Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 477-479

  Lieberman, Ronald ^a  

^a IQVIA   (United States)

Author keywords

Colorectal cancer; EGFR; KRAS; Monoclonal antibodies; Personalized medicine

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEALTH CARE SYSTEM; HUMAN; INSURANCE; LUNG ADENOCARCINOMA; MEDICAL SOCIETY; MONOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; SHORT SURVEY; SOCIOECONOMICS; TREATMENT RESPONSE; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MARKETING; MUTATION; PATIENT SELECTION; PHARMACOGENETICS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; UNITED STATES;

EID: 74549159630     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181baf276     Document Type: Short Survey

References (12)

1. The Pink Sheet, April 6, 2009;25.
2. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther. 2009;16:554-561.
3. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio E, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancer to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648.
5. Razis E, Briasoulis E, Vrettou E, et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer. 2008;8:234.
6. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237.
7. Mok TS, Leong SS, Liu X, et al. Gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS): randomized, open-label, phase III study (abstract). J Thorac Oncol. 2008;3:S302.
8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23: 5900-5909.
9. O'byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC). Data from the FLEX study. J Clin Oncol. 2009;27:S8007.
10. Perner S, Wagner P, Demichelis F, et al. EMLA-ALK fusion lung cancer. A rare acquired event. Neoplasia. 2008; 10:298-302.
11. Shaw AT, Costa D, Mino-Knudsen M, et al. Clinicopathologic features of EML4-ALK mutant lung cancer. J Clin Oncol. 2009;27:S563.
12. The Pink Sheet. April 13, 2009; 7.